Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

Asia Executives On The Move: Merck, Takeda, Ono, Simcere

Wed, 08/07/2019 - 6:06pm

Merck China former R&D head returns after a short stint with startup Ascletis, and Takeda has a new center director...

      Related Stories 

Cutbacks Rise As Indian Pharma Tightens Control On Costs

Wed, 08/07/2019 - 4:59pm

Leading Indian pharma firms are rationalizing operations and work forces to rein in costs and improve efficiency and profitability in...

      Related Stories 

Rhythm Preparing NDA Submission In Rare Genetic Obesity Disorders

Wed, 08/07/2019 - 3:16pm

Setmelanotide reduced feelings of hunger in patients with POMC and LEPR deficiency obesities and helped many lose weight, with some...

      Related Stories 

Opioid Litigation Clouds Loom Over Teva's Turnaround

Wed, 08/07/2019 - 12:50pm

Increasing uncertainty over Teva's liability in opioid litigation is weighing on the generic drug manufacturer, even as the North American...

      Related Stories 

PROfound Puts Lynparza On Track For Prostate Cancer Indication

Wed, 08/07/2019 - 9:38am

AstraZeneca and Merck & Co said their PARP inhibitor Lynparza has become the first to show positive Phase III trial...

      Related Stories 

Novartis Battens Down Hatches Over Falsified Zolgensma Data

Wed, 08/07/2019 - 8:36am

The Swiss major believes it responded in a timely fashion to data manipulation issues associated with its closely watched gene...

      Related Stories 

Basilea's Ceftobiprole On TARGET, Needs Positive Second Study For US

Wed, 08/07/2019 - 8:20am

The first pivotal Phase III study required for US approval of Basilea’s ceftobiprole has reported positive topline results; a second...

      Related Stories 

E2082 Discontinuation May Hit Eisai's Epilepsy Succession

Tue, 08/06/2019 - 5:08pm

Fatality of healthy volunteer in early clinical trial prompts halt of all clinical work for candidate anti-epileptic, potentially hitting Eisai's...

      Related Stories 

Sage's Zulresso Launch Is Off, But Not Running

Tue, 08/06/2019 - 12:13pm

The company updated investors on the launch of the first treatment for postpartum depression during its Q2 earnings call. More...

      Related Stories 

Mologen To Pursue Combinations Only After Lefitolimod’s Solo IMPALA Failure

Tue, 08/06/2019 - 8:30am

Mologen’s CEO tells Scrip the German biotech will only pursue combination studies in future after its lead candidate lefitolimod failed as...

      Related Stories 

Top 10 Drugs: Weighing Pharma's Golden Eggs

Tue, 08/06/2019 - 7:57am

INFOGRAPHIC: A relatively small number of relatively costly drugs account for a sizable proportion of pharma industry revenues. But what...

      Related Stories 

Getting A Good Start: Sanofi Extends Dupixent's Potential To Younger Patients

Tue, 08/06/2019 - 7:33am

Sanofi/Regeneron’s pioneering biologic, dupilumab, is growing its potential market before the advent of competing molecules. An EU approval extension, allowing...

      Related Stories 

Mylan-Biocon’s Ogivri First Off Block In Australia But Competition In Sight

Mon, 08/05/2019 - 6:41pm

Mylan-Biocon’s biosimilar Herceptin debuts in Australia, promising to provide patients a high quality and affordable alternative, though at least three...

      Related Stories 

Tecentriq Plus Chemo Data Could Re-Enforce Roche's Position In Bladder Cancer

Mon, 08/05/2019 - 3:55pm

Roche's PD-L1 inhibitor Tecentriq in combination with chemotherapy improved progression-free survival in first-line bladder cancer, after the immunotherapy failed a...

      Related Stories 

AbbVie Revs Up The Race To Market In Uterine Fibroids

Mon, 08/05/2019 - 1:05pm

AbbVie and Neurocrine submitted an NDA to FDA for elagolix for bleeding associated with uterine fibroids, leading in what is...

      Related Stories 

Sickle Blow For Pfizer’s Rivipansel At Phase III RESETs Expectations

Mon, 08/05/2019 - 9:01am

After a long wait, the top-line data for Pfizer’s RESET study of the investigational treatment for sickle cell disease disappoint...

      Related Stories 

Sosei Heptares Bags Second GPCR Targets Deal In A Month, With Takeda

Mon, 08/05/2019 - 9:01am

The Japanese biotech agreed a multi-year, multi-target research collaboration and license deal with Takeda to discover and develop medicines that...

      Related Stories 

Transgene Downplays Impact Of Pexa-Vec Phase III Cancer Trial Failure

Mon, 08/05/2019 - 8:16am

A late-phase assessment of the oncolytic virus in liver cancer patients was stopped early for futility but Transgene thinks the...

      Related Stories 

Pages